F046 HS Surgery from Start to Finish: Planning, Procedures, and Post-op Care
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
While most inflammatory conditions treated by dermatologists are managed with medications alone, surgery is an integral part in the care of patients with hidradenitis suppurativa (HS). This session aims to provide practical tips for dermatologists interested in adding surgical procedures to their repertoire, and to improve the skills and confidence of those already performing clinic-based procedures. Additional emphasis will be placed on identifying patients that are appropriate for referral to surgical specialists, and understanding what can be accomplished for patients with extensive surgical needs. Further education on options for wound management and troubleshooting wound complications will be provided.
LEARNING OBJECTIVES
Prepare for and proceed with office-based surgical management for HS.
Identify patients that are appropriate for referral to surgical specialists.
Manage wounds and post-operative complications for patients with HS.
SCHEDULE
5:00 PM
Preoperative planning and expectation setting
Venessa Pena-Robichaux, MD, FAAD
5:20 PM
Clinic based surgical and laser treatments
Iltefat H. Hamzavi, MD, FAAD
5:40 PM
Options for managing extensive disease of the external genitals
Stephanie Goldberg, MD
6:00 PM
Q&A session
Venessa Pena-Robichaux, MD, FAAD, Stephanie Goldberg, MD, Iltefat H. Hamzavi, MD, FAAD
6:10 PM
Advantages and limitations to operating room-based approaches
Falk Bechara
6:30 PM
Managing wounds and complications in the post-operative period
Drew Kenith Saylor, MD, FAAD
6:50 PM
Q&A session
Falk Bechara, Drew Kenith Saylor, MD, FAAD
SPEAKERS
Falk Bechara
Stephanie Goldberg, MD
Iltefat H. Hamzavi, MD, FAAD
Venessa Pena-Robichaux, MD, FAAD
Drew Kenith Saylor, MD, FAAD
HANDOUTS
SPEAKER DISCLOSURES
Falk Bechara
AbbVie – Advisory Board(Fees); Acelyrin – Other(Fees); Boehringer Ingelheim – Other(Fees); Celltrion – Advisory Board(Fees); Dr. August Wolff GmbH& Co. – Advisory Board(Fees); Incyte – Other(Fees); Janssen-Cilag – Speaker(Fees); Mölnlycke – Other(Fees); MoonLake Immunotherapeutics – Advisory Board(Fees); Novartis – Speaker(Fees); UCB Pharma – Speaker(Fees);
Stephanie Goldberg, MD
Novartis – Advisory Board(Honoraria); UCB – Consultant (1099 relationship)(Honoraria);
Iltefat H. Hamzavi, MD, FAAD
AbbVie – Advisory Board(Fees); Almirall – Consultant (1099 relationship)(Fees); Avita – Investigator(Grants/Research Funding); Beiersdorf, Inc. – Advisory Board(Fees); Boehringer Ingelheim – Consultant(Fees); Clinuvel – Investigator(Fees); Galderma Laboratories, L.P. – Investigator(Fees); Global Vitiligo Foundation – Board of Directors(No Compensation Received); Hidradenitis Suppurativa Foundation – Board of Directors(No Compensation Received); Incyte Corporation – Investigator(Grants/Research Funding); Janssen Biotech – Investigator(Grants/Research Funding); L'Oreal USA Inc. – Investigator(Grants/Research Funding); Lenicura – Investigator(Equipment); MyDerm Portal, Inc – Stockholder(Stock); Novartis – Consultant(Fees); Pfizer Inc. – Investigator(Fees); Sonoma Biotherapeutics – Investigator(Grants/Research Funding); UCB – Consultant(Fees); Union Therapeutics – Consultant(Fees); Vimela – Consultant (1099 relationship)(Fees);
Venessa Pena-Robichaux, MD, FAAD
Osquo – Other(Stock);
Drew Kenith Saylor, MD, FAAD
No financial relationships exist with ineligible companies.